Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

News Conference News HRS 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

Michael O'Riordan

May 23, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

April 12, 2024

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

October 13, 2023

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

News Conference News ESC 2023

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

Yael L. Maxwell

August 31, 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

May 25, 2023

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

May 13, 2020

ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year

News Conference News TCT 2018

ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year

September 24, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.